Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review
FE von Eyben, K Kairemo, DS Kapp - Biomedicines, 2024 - mdpi.com
Serum prostate-specific antigen (PSA) needs to be monitored with ultrasensitive PSA assays
(uPSAs) for oncologists to be able to start salvage radiotherapy (SRT) while PSA is< 0.5 …
(uPSAs) for oncologists to be able to start salvage radiotherapy (SRT) while PSA is< 0.5 …
[HTML][HTML] The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024
In the past, selection of intermediate clinical endpoints (ICEs) in prostate cancer (PCa) trials
largely depended on qualitative assessments; however, the advancing quality of research …
largely depended on qualitative assessments; however, the advancing quality of research …
[引用][C] Prostate-Specific Antigen Nadir Postradiotherapy in Localized Prostate Cancer: Is It Prognostic or Predictive?
DE Spratt - Journal of Clinical Oncology, 2024 - ascopubs.org
Localized prostate cancer, the most prevalent cancer and disease state among men, is
predominantly managed through risk stratification. Despite its ubiquity, conventional risk …
predominantly managed through risk stratification. Despite its ubiquity, conventional risk …